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Abstract
Background/aims: Dose-escalation studies are essential in the early stages of developing novel treatments,
when the aim is to find a safe dose for administration in humans. Despite their great importance, many dose-
escalation studies use study designs based on heuristic algorithms with well-documented drawbacks. Bayesian
decision procedures provide a design alternative that is conceptually simple and methodologically sound, but very
rarely used in practice, at least in part due to their perceived statistical complexity. There are currently very few
easily accessible software implementations that would facilitate their application.
Methods: We have created MoDEsT, a free and easy-to-use web application for designing and conducting single-
agent dose-escalation studies with a binary toxicity endpoint, where the objective is to estimate the maximum
tolerated dose. MoDEsT uses a well-established Bayesian decision procedure based on logistic regression. The
software has a user-friendly point-and-click interface, makes changes visible in real time, and automatically generates
a range of graphs, tables, and reports. It is aimed at clinicians as well as statisticians with limited expertise
in model-based dose-escalation designs, and does not require any statistical programming skills to evaluate the
operating characteristics of, or implement, the Bayesian dose-escalation design.
Results: MoDEsT comes in two parts: a ‘Design’ module to explore design options and simulate their operating
characteristics, and a ‘Conduct’ module to guide the dose-finding process throughout the study. We illustrate the
practical use of both modules with data from a real phase I study in terminal cancer.
Conclusion: Enabling both methodologists and clinicians to understand and apply model-based study designs
with ease is a key factor towards their routine use in early-phase studies. We hope that MoDEsT will enable
incorporation of Bayesian decision procedures for dose escalation at the earliest stage of clinical trial design, thus
increasing their use in early-phase trials.
Keywords: Phase I clinical trial, dose-finding study, logistic model, Bayesian statistics, graphical user interface, shiny
app, R software
1 Introduction
The primary aim of many phase I dose-escalation studies is to estimate the maximum tolerated dose of a novel drug
or treatment. In practice this often means identifying a dose for which the probability of a patient developing a
dose-limiting toxicity is close to a prespecified target toxicity level, typically between 0.20 and 0.33 in cancer trials.
Patients enter the study in cohorts of one or more (usually three), and for every new cohort a decision is made whether
to stay at the current dose level, escalate or de-escalate the dose, or stop the study entirely. A statistical study design
informs and guides this process, but the ultimate decision will always be based on clinical judgement.
It is good practice that early-phase dose escalation designs use a well-fitting statistical model to synthesise all available
information (from prior knowledge and accumulating patient data) and deduce a recommendation for how to proceed
with the study. Love et al. (2017); Wheeler et al. (2019) The first model-based designs were developed in the 1990s,
most prominently the continual reassessment method O’Quigley et al. (1990), and also Bayesian decision procedures,
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Whitehead and Brunier (1995); Whitehead and Williamson (1998) which are closely related to one another. Shu and
O’Quigley (2008)
The alternative to model-based designs are methods that rely on largely heuristic rules or algorithms, such as the 3+3
design. The only real virtue of these algorithms is their simplicity (at least when nothing unforeseen happens), but on
the downside they are less likely to identify the correct maximum tolerated dose than model-based designs, require on
average more patients to reach a dose recommendation, have less flexibility to accommodate deviations from the pre-
specified dose-escalation procedure, and lack any theoretical foundation. Jaki et al. (2013); Paoletti et al. (2015); Nie
et al. (2016); Adaptive Designs Working Group of the MRC Network of Hubs for Trials Methodology Research (2016)
Despite these clear drawbacks, rule-based designs are still in wide use, while the uptake of model-based designs remains
slow, especially in the public sector. Jaki (2013); van Brummelen et al. (2016); Chiuzan et al. (2017) Unfortunately,
the latter appear to many as a black box requiring specialist statistical input—which they are notYap et al. (2017).
There is also a misconception that they are overly complicated because they require more planning than rule-based
designs, such as the choice of a prior probability distribution (or ‘prior’ for short).
In this paper we introduce MoDEsT (Model-based Dose Escalation Trials), a free and easy-to-use web tool for designing
and conducting single-agent dose-escalation studies guided by a Bayesian decision procedure to estimate the maximum
tolerated dose. Zhou and Whitehead (2003) This method is conceptually straightforward and statistically sound:
it uses logistic regression to model the relationship between dose and risk of toxicity and allows the investigator to
specify prior distributions for dose-toxicity model parameters through the means of ‘pseudo-observations.’ These
pseudo-observations should represent our best guesses, prior to the start of the study, at the toxicity outcomes that
would be recorded if hypothetical (i.e. pseudo-)patients were administered certain doses of the compound. Usually,
priors are specified by stipulating pseudo-observations for the lowest and highest doses available for administration
during the future study. Prior specification can be informed by a scientific understanding of the drug’s anticipated
mechanism of action. Alternatively, the pseudo-observations can be set so as to ensure the procedure has favourable
operating characteristics (so-called ‘operational priors’).
Onerous tasks that are currently a barrier to the use of model-based designs, like setting a prior, become easy with
MoDEsT: it allows trying out different priors and immediately visualises the consequences in terms of the operating
characteristics (e.g. probability of identifying the correct maximum tolerated dose, expected number of patients
required) of the procedure. This provides users with insight as to how dose recommendations come about, thus
demystifying the model-based design.
In contrast to most other software for study design, MoDEsT is specifically aimed at both clinical trialists and
statisticians with no previous experience of model-based dose escalation who would default to the 3+3 design for
simplicity, although we believe it is also useful for statistical experts who already have a thorough understanding of
model-based dose escalation. The intuitive point-and-click interface of MoDEsT encourages users to explore a variety
design options, allows them to watch changes become effective in real time, and get a feel for the design’s performance
in different clinically relevant scenarios. It facilitates the consideration and inclusion of efficient model-based dose
escalation at the earliest stage of clinical trial design, which should always be a collaborative effort between clinical
and statistical experts.
MoDEsT was written in the R R Core Team (2017) programming language and using the extension package shiny,
Chang et al. (2017) which provides a framework for building interactive web applications. shiny is steadily gaining
popularity in the context of methods for early-phase dose finding. Recent years have seen the development of shiny
apps to
• design and run dose-escalation studies using the continual reassessment method, Wages and Petroni (2018)
• design dual-agent dose-escalation studies, Sweeting (2017)
• compare the performances of various model- and rule-based designs, Wheeler et al. (2016); Chen and Shyr (2017)
• simulate the highest achievable (i.e. optimal benchmark) accuracy when selecting the maximum tolerated dose.
Wages and Varhegyi (2017)
There are also a number of graphical user interfaces for dose-finding methods that are not based on shiny, such as
‘NextGen-DF’ (now called ‘U-Design’) Yang et al. (2015), ‘Web-EWOC’ Rogatko et al. (2017), a plethora of tools pro-
vided by the MD Anderson Cancer Center (https://biostatistics.mdanderson.org/softwaredownload), and commercial
packages such as EAST Escalate (https://www.cytel.com/software/east) and FACTS (https://www.berryconsultants.com/software).
To the best of our knowledge, none of them holds any functionality for the method outlined above. The only software
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implementation of this method that we are aware of is ‘Bayesian ADEPT’, Zhou and Whitehead (2002); Bedding
(2003) which has been defunct for several years. Further distinct strengths of MoDEsT are:
1. it runs under any operating system;
2. it does not require any software package to be installed;
3. its point-and-click interface means no specialist software or programming skills are required;
4. it automatically generates PDF reports;
5. it is free to use.
2 Methods
2.1 Bayesian decision procedure
The Bayesian decision procedure implemented in MoDEsT is made up of four main components: 1) a logistic regression
model, 2) prior information about the dose-toxicity relationship, 3) a gain function, and 4) a set of rules for (de-)
escalating the dose and stopping the study. We describe each component briefly below; for a detailed exposition we
refer to the original paper by Zhou & Whitehead. Zhou and Whitehead (2003)
2.1.1 1) Logistic model.
We assume the relationship between dose and risk of toxicity follows a logistic model
log
(
P(dose-limiting toxicity)
1− P(dose-limiting toxicity)
)
= β0 + β1 log(dose)
where the logit transformation of the probability (i.e. the log odds) of observing a dose-limiting toxicity (left-hand
side of the equation is assumed to depend on the log-transformed dose in a linear fashion (right-hand side of the
equation; see the illustration in Figure 1. We use toxicity data from study patients to estimate the values of the model
parameters β0 (intercept) and β1 (slope).
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Figure 1: Example of an S-shaped dose-toxicity curve (left) and the corresponding straight line after transformation
(right). The dotted horizontal line indates a target toxicity level of 0.3, or log(0.3/0.7)=–0.847 on the logit scale.
P(DLT) is the probability of a dose-limiting toxicity.
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2.1.2 2) Prior information.
To get the Bayesian decision procedure started before any patient data are available, we need prior information on
the dose-toxicity relationship. Guessing values of the model parameters β0 and β1 would be hard, so we prefer to
formulate our prior beliefs about the toxicity rates of two distinct doses. The strength of these beliefs can be expressed
in terms of their ‘effective sample sizes’ Morita et al. (2008): the information from, say, 3 pseudo-observations will be
weighted as if they had been obtained from 3 real patients, and mathematically converted into so-called beta priors.
Zhou and Whitehead (2003)
2.1.3 3) Gain function.
A gain function can be used to quantify, for each dose, the advantage of prescribing different dose levels to the next
cohort of patients, where larger gains are to be preferred. Thus the gain function helps to determine which dose should
be recommended for the next patient cohort. The ‘patient gain’ function would assign the dose currently thought to
be closest to the target toxicity level (which is optimal from a current patient’s perspective) whereas the ‘variance
gain’ function would choose the dose that will likely maximise learning about the dose-toxicity relationship (which is
optimal from an investigator’s perspective and also from the perspective of future patients who will be treated beyond
the current clinical trial). Whitehead and Williamson (1998) In practice the choice of gain function is unlikely to have
a significant impact on the performance characteristics of the study design, but this can be explored in MoDEsT.
2.1.4 4) Escalation and stopping rules.
Dose recommendations are determined primarily by the model and the gain function, but we may wish to apply
additional restrictions such as:
• always start at the lowest dose;
• do not skip over any doses when escalating;
• do not escalate upon observing a toxicity in the current cohort.
Stopping recruitment to the study will be recommended once
• the maximum number of patients have been analysed;
• a pre-defined maximum number of consecutive patients receiving the same dose has been reached;
• a sufficiently accurate estimate of the maximum tolerated dose has been obtained;
• no dose among those in the pre-specified set is deemed safe.
3 Results
3.1 The MoDEsT app
MoDEsT comes in two parts: a ‘Design’ module to investigate candidate design options and simulate their operating
characteristics, and a ‘Conduct’ module to guide decision making throughout the study, incorporate accruing patient
data into the model and provide summaries of the final dataset on completion of the study. Both modules are fully
reactive i.e. changes made by the user become effective in real time. MoDEsT can be accessed online (https://medstats-
lancs.shinyapps.io/design/ and https://medstats-lancs.shinyapps.io/conduct/) from any device with a web browser.
For R users the app is also available in the add-on package modest. Pallmann and Wan (2017) We will keep maintaining
both the web app and the R package (including bug fixes and possibly adding new options), hence the appearance and
functionality of MoDEsT may change slightly as it evolves.
3.1.1 The ‘Design’ module.
The ‘Design’ module takes as inputs the basic study parameters (maximum sample size, cohort size, dose levels, target
toxicity level, gain function), the pseudo-observations needed to specify prior distributions for parameters of the dose-
toxicity model, ‘true’ values of model parameters for simulation of the Bayesian procedure in different scenarios, and
additional escalation and stopping rules as detailed above; all these are conveniently specified via sliders, text and tick
boxes (Figure 3). The app then creates graphical displays of the dose-toxicity curves, simulates an example of a study
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given the current specifications, and suggests a variety of scenarios1 for use in a subsequent simulation study (Figure
4). For the scenario chosen MoDEsT assesses a variety of operating characteristics and presents the results in tables
and graphics. On the basis of the inputs the app generates a CSV design file that can subsequently be fed into the
‘Conduct’ module. Additionally a report summarising the design, prior information, and simulation results can be
downloaded in PDF format.
3.1.2 The ‘Conduct’ module.
The ‘Conduct’ module requires the user to upload a design file (obtained from the ‘Design’ module) and supply
(anonymised) patient data. The latter can either be uploaded as a CSV file (typically created with a text editor or
spreadsheet software such as Microsoft Excel, OpenOffice/LibreOffice Calc, or Google Sheets), or entered manually
via a spreadsheet interface. The app then produces graphical displays of the data, fits the logistic model, calculates
the current estimate of the maximum tolerated dose, and recommends either a dose for the next cohort or stopping
the study in case a relevant criterion is fulfilled (Figure 5). A PDF report summarising the design, data, analysis, and
recommendation is available for download. This can all be easily produced by the clinical study team for each dose
review meeting so that dose recommendations based on statistical analyses of current and past patient data are used
real-time alongside clinical opinion from the investigators to decide on dosing for the next patient cohort.
3.1.3 Getting help.
While the app’s user guidance should be intuitive and most inputs and outputs self-explanatory, additional help may oc-
casionally be required. The quickest way to learn more about an input element (e.g. slider, button, check box, text box)
is by mousing over it, and a tooltip will appear. A full description/documentation of all of MoDEsT’s functionality along
with a detailed explanation of all inputs and outputs is given in the help pages on the website. They are also included in
the R package in the form of two HTML vignettes (https://cran.r-project.org/web/packages/modest/vignettes/Design.html
and https://cran.r-project.org/web/packages/modest/vignettes/Conduct.html).
3.2 Example: a phase I study of quercetin
The workflow when designing and conducting a study with MoDEsT is best illustrated with a real data example. In
the following we re-design and re-analyse (parts of) a dose-escalation study of a novel drug product in terminal cancer
that originally used a 3+3-type design with several spontaneous modifications.
3.2.1 Dataset.
Ferry et al. conducted a phase I study of the flavonoid quercetin in cancer patients suffering from a variety of forms of
solid tumour no longer amenable to standard therapies. Ferry et al. (1996) They assessed 9 dose levels (60, 120, 200,
300, 420, 630, 945, 1400, 1700 mg/m2) with the aim of finding the maximum tolerated dose under the premise that a
20% risk of renal toxicity (WHO grade ≥ 2) would be acceptable. A maximum of 18 patient cohorts of size 3 was to
be recruited to the study.
Figure 2 provides an overview of the study data from a total of 52 patients. We note a number of oddities and decisions
made against the rules of 3+3:
• The dose was escalated to 1400 mg/m2 for the 8th cohort despite a dose-limiting toxicity having been recorded
for the 7th cohort at 945 mg/m2.
• Dose-limiting toxicities occurred in both the 10th and 11th cohort at 1400 mg/m2, and yet the dose was not
de-escalated for the 12th cohort.
• No dose-limiting toxicities occurred in the 12th cohort, but the dose was de-escalated for the 13th cohort to 945
mg/m2.
• The 12th cohort consisted of 4 patients.
• A dose-limiting toxicity was recorded for the 17th cohort at 630 mg/m2, still the dose was escalated to 945
mg/m2 for the 18th cohort.
• The 16th, 17th, and 18th cohort each consisted of 2 patients only.
1The simulation scenarios are based on Table 1 of Zhou & Whitehead (2003) Zhou and Whitehead (2003) and Table 7.9 of Whitehead
(2006). Whitehead (2006)
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Figure 2: Overview of the quercetin study data.
These deviations cannot be incorporated within the 3+3 design with its inherent inflexibility. This design no longer
provides a relevant contribution to dose-escalation decisions, whereas the model-based procedure implemented in
MoDEsT can easily handle cohorts of non-standard size and dose recommendations overruled by clinical judgement.
3.2.2 Study design.
We set the study design parameters (maximum sample size, cohort size, dose levels, target toxicity level) as in Ferry
et al.’s original study and use the patient gain function to drive dose-escalation recommendations (Figure 3). We
specify a ‘pessimistic’ or ‘conservative’ prior distribution for parameters of the dose-toxicity relationship by specifying
pseudo-observations consistent with the opinion that, a priori, we would expect to see 0.3 dose-limiting toxicities if 3
patients were treated with 60 mg/m2 and 1.5 dose-limiting toxicities if 3 patients received 1700 mg/m2, corresponding
to anticipated dose-limiting toxicity risks of 10% and 50%, respectively. Note that non-integer values of dose-limiting
toxicities are acceptable when specifying prior distributions. For the assumed ‘true’ dose-toxicity model used to
simulate dose-limiting toxicity occurrences we choose the ‘true’ dose-limiting toxicity risks on the lowest and highest
doses to be 3% and 40%, respectively. One does not necessarily have to specify priors by considering dose-limiting
toxicity risks on the lowest and highest dose levels, but we do recommend choosing one dose at the lower and one at
the upper end of the spectrum.
For the purpose of this example, we enforce starting at the lowest dose, not skipping over any doses when escalating,
and not escalating when a dose-limiting toxicity occurs in the current cohort. We consider trial designs which would
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recommend stopping the study for accuracy once 12 consecutive patients have received the same dose, or when the
ratio of the upper and lower 95% credible limit around the estimated maximum tolerated dose is 3 or less.
Figure 3: Input mask of the ‘Design’ module with specifications inspired by the quercetin study.
From these inputs MoDEsT generates a number of graphs and tables to summarise the operating characteristics of
the stipulated design. We see that if our simulation model were indeed the true dose-toxicity curve, the maximum
tolerated dose would be estimated as 584 mg/m2, but only 206 mg/m2 under the much more cautious prior model
(Figure 4, top left panel). Unsurprisingly, the 95% credible band around the prior curve is extremely wide, as it is
based on only 3 (pseudo-)observations.
MoDEsT displays one simulated realisation of a study which proceeds according to the proposed Bayesian dose-
escalation procedure and stopping rules, simulating patient outcomes setting dose-limiting toxicity risks equal to
values consistent with the current dose-toxicity simulation model. This is intended as an illustrative example of what
the study could look like. A single simulated dataset, and the corresponding evolution of the dose-escalation trial, will
not necessarily be representative of what would typically be observed if the true underlying dose-toxicity relationship
was identical to the simulation model. However, by simulating a large number of trials and averaging across them,
we can deduce what might happen on average. MoDEsT is designed to allow easy repeated simulation, which will be
helpful in getting a feel for the variation of output that can occur.
The example trial shown in Figure 4 (top right panel) is stopped after 12 cohorts, when 12 consecutive patients have
received the same dose (420 mg/m2), upon de-escalation from 630 mg/m2). The 95% credible band for the maximum
tolerated dose becomes narrower over the course of the study and always contains the ‘true’ value of 584 mg/m2.
To facilitate assessment of the design’s operating characteristics, MoDEsT automatically creates six simulation sce-
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Figure 4: Top left: ‘Model’ tab of the ‘Design’ module displaying the prior and the assumed true dose-toxicity curve.
Top right: ‘Example’ tab of the ‘Design’ module showing one simulated example dataset. Bottom left: ‘Scenarios’ tab
of the ‘Design’ module giving an overview of six simulation scenarios. Bottom right: ‘Simulations’ tab of the ‘Design’
module summarising simulation results.
narios that can be used in the simulation study: the standard scenario defined by the ‘true’ simulation model, and
five additional scenarios derived from it that imply lower (‘inactive’) or higher (‘potent’) toxicity rates over the whole
dose range or parts of it. They are summarised in a table and graph, alongside the prior for comparison (Figure 4,
bottom left panel).
Figure 4 (bottom right panel) shows summary tables and graphs of 1000 simulations performed within seconds by the
press of a button under the (anticipated) standard scenario. In this example the average sample size required was 36.28
patients (averaged over all 1000 simulated trials), the average of the maximum likelihood estimate of the maximum
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tolerated dose was 649.86 mg/m2, with a large mean squared error and notable bias, and an average toxicity rate of
14%, which is well below the targeted 20%. We see how many simulated trials were stopped for which reason(s); the
sum of the percentages is greater than 100% because multiple stopping criteria can be fulfilled at the same time. We
also get an overview of the sample sizes used, numbers of dose-limiting toxicities observed, reasons for stopping, and
doses recommended as the maximum tolerated dose across the 1000 simulated trials. These summary plots and tables
produced instantly by MoDEsT will be sufficient for most users but a detailed account of all individual simulation
runs can be downloaded as a CSV file.
3.2.3 Study conduct.
For illustrative purposes we present and discuss here only the analyses following the 7th and the last cohort, respectively;
in practice a similar analysis would be performed after every single patient cohort.
We upload the design file and a CSV containing the study data. MoDEsT generates tabular overviews of the design
parameters and patient data, as well as plots such as the one in Figure 2. We recommend that users review this
output to double-check the information and also whether data have been read in as intended i.e. correct columns were
specified for the cohort, dose, and response variable.
In Ferry et al.’s study the dose was escalated from 945 to 1400 mg/m2 for the 8th cohort, despite a dose-limiting toxicity
being observed in the 7th cohort (Figure 2). Re-analysing the data up to and including the 7th cohort with MoDEsT,
we find that the Bayesian dose-escalation procedure recommends administering 945 mg/m2 to the 8th patient cohort
(Figure 5, left panel), which is in line with our the stipulated safety rule of not escalating when a dose-limiting toxicity
has been observed in the current cohort. Due to the amount of data accruing, the 95% credible band is much narrower
than for the prior.
The dataset accrued upon completion of the study comprises 52 patients, which is less then the envisaged maximum
sample size of 54, so we have to tick the box in MoDEsT to indicate that the study has been stopped (Figure 5,
right panel). The final model-based estimate of the maximum tolerated dose is 998 mg/m2, but this is influenced by
the very pessimistic prior. Removing the pseudo-observations used to formulate the prior yields a final (maximum
likelihood) estimate of 1090 mg/m2 and a marginally wider credible band. Both estimates lead to a recommendation
of 945 mg/m2 for the maximum tolerated dose, which is the same as in Ferry et al. However, had MoDEsT been
used in the original study, the deviations from the protocol (such as smaller and larger cohorts) could easily have been
accommodated, and the (clearly too high) dose of 1700 mg/m2 would probably never2 have been administered.
Figure 5: ‘Recommendation’ tab of the ‘Conduct’ module after the 7th cohort (left) and after the final analysis (right)
of the quercetin study.
2Simulations with the final model of Figure 5 (right panel) as the ‘true’ simulation model show that it is extremely unlikely to ever visit
this dose level.
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4 Discussion
Building trust in the utility, safety, and practical applicability of model-based dose-escalation designs is an essential
step towards their wider acceptance within the clinical community. To assist this process we have created MoDEsT, a
software tool that is straightforward to use even without any specialist knowledge of statistical programming. We are
positive it will convince trialists and statisticians that model-based methods are a feasible and worthwhile alternative
to the 3+3 design and can be implemented with limited additional effort. Tasks that currently discourage many
clinicians from using model-based designs, like having to set a prior, are made simple in MoDEsT. One of the main
advantages of the software is that it allows investigators to input different (hypothetical or real) datasets ahead of time
to see what dose recommendations the Bayesian dose-escalation procedure would generate, allowing them to develop
some intuition as to how the procedure is working and how it would compare with their own intuition or algorithmic
rules they might be more familiar with. We hope that by seeing the effects of changing design parameters in real time,
trialists will become more confident in using model-based designs and that these will increasingly become the norm in
early-phase dose-escalation studies.
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